(3S)-3-羟基-3-苯基丁烷-2-酮 | 42843-19-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (3S)-3-羟基-3-苯基丁烷-2-酮
• 英文名称: (S)-3-hydroxy-3-phenyl-2-butanone
• 英文别名: (3S)-3-Hydroxy-3-phenylbutan-2-one
• CAS: 42843-19-6
• 化学式: C₁₀H₁₂O₂
• 分子量: 164.204
• InChiKey: IBWFPYRVHYLXEU-SNVBAGLBSA-N

物化性质

• 沸点：
  103-105 °C(Press: 5 Torr)
• 密度：
  1.089±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-苯基-3-丁炔-2-醇 在 lithium aluminium tetrahydride 、 三氯化铝 、 Sharpless β-AD mix 作用下， 生成 (3S)-3-羟基-3-苯基丁烷-2-酮
  参考文献：
  名称：

  Asymmetric dihydroxylation of disubstituted allenes

  摘要：

  Asymmetric dihydroxylation of 1,1-disubstituted and 1,3-disubstituted allenes can be used to synthesize chiral alpha-hydroxy ketones. We have also obtained alpha,alpha'-dihydroxy ketones with high enantioselectivity from 1,3-disubstituted allenes. Low conversion of the dihydroxylation of chiral allenes can be used as a kinetic resolution of sterically hindered allenes. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2005.09.138

文献信息

• [EN] LINKED DIBENZIMIDAZOLE DERIVATIVES<br/>[FR] DÉRIVÉS DU DIBENZIMIDAZOLE LIÉS
  申请人：ENANTA PHARM INC

  公开号：WO2010091413A1

  公开（公告）日：2010-08-12

  The present invention discloses linked dibenzimidazole derivatives, or pharmaceutically acceptable salts, esters, or prodrugs thereof, which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了联苯二咪唑衍生物，或其药学上可接受的盐、酯或前药，其抑制含RNA的病毒，特别是丙型肝炎病毒（HCV）。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，并且也可用作抗病毒剂。本发明还涉及包括上述化合物的药物组合物，用于治疗患有HCV感染的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
• HEPATITIS C VIRUS INHIBITORS
  申请人：Qiu Yao-Ling

  公开号：US20110064695A1

  公开（公告）日：2011-03-17

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with said compounds.

  本发明公开了化合物的结构式（I），或其药学上可接受的盐、酯或前药： 这些化合物抑制RNA含病毒，特别是丙型肝炎病毒（HCV）。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，并且也可用作抗病毒剂。本发明还涉及包含上述化合物的药物组合物，用于治疗患有HCV感染的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。本发明涉及上述新型抗病毒化合物，包括含有这些化合物的药物组合物，以及用于治疗或预防受试者需要此类治疗的病毒（特别是HCV）感染的方法。
• [EN] HEPATITIS C VIRUS INHIBITORS<br/>[FR] INHIBITEURS DU VIRUS DE L'HÉPATITE C
  申请人：ENANTA PHARM INC

  公开号：WO2010099527A1

  公开（公告）日：2010-09-02

  The present invention discloses compounds or pharmaceutically acceptable salts, esters, or prodrugs thereof, which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了抑制RNA含病毒，特别是丙型肝炎病毒（HCV）的化合物或药用可接受的盐、酯或前药，因此，本发明的化合物干扰丙型肝炎病毒的生命周期，并且也可用作抗病毒剂。本发明还涉及包含上述化合物的药物组合物，用于治疗患有HCV感染的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
• Hepatitis C Virus Inhibitors
  申请人：Bachand Carol

  公开号：US20080050336A1

  公开（公告）日：2008-02-28

  The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

  本公开涉及化合物、组合物和治疗丙型肝炎病毒（HCV）感染的方法。还公开了含有这些化合物的药物组合物以及使用这些化合物治疗HCV感染的方法。
• [EN] A NOVEL METHOD FOR SYNTHESIS OF OPTICALLY PURE BETA-AMINO ALCOHOLS<br/>[FR] NOUVEAU PROCÉDÉ DE SYNTHÈSE DE BÊTA-AMINO ALCOOLS OPTIQUEMENT PURS
  申请人：EMBIO LTD

  公开号：WO2015198108A1

  公开（公告）日：2015-12-30

  A method for the preparation of β-amino alcohol of formula (III) in which R1 is Ph, (substituted) Ph, R2 is C1-8 alkyl or C4-6 cyclo alkyl, R3 = R4R5CHNH2 where, R4 = H, C1-8 alkyl, C4-6 cyclo alkyl, or - COOR6 (R6=C1-C8 alkyl); R5 = (subst) aryl], the method including subjecting an α-hydroxy ketone of formula (I) in which R1 and R2 are as defined above is reacted with a chiral amine of formula R3NH2 where R3 = R4R5CH- where, R4 = H, C1-8 alkyl, C4-6 cycloalkyl, or - COOR6 (R6=C1-8 alkyl), R5 = (subst) aryl] to produce a compound of formula (II) in which R1, R2 and R3 are as defined above, followed by reduction to form the compound of formula (III).

  一种制备β-氨基醇的方法，其化学式为(III)，其中R1为苯基、(取代)苯基，R2为C1-8烷基或C4-6环烷基，R3 = R4R5CHNH2，其中，R4 = H、C1-8烷基、C4-6环烷基或-COOR6 (R6=C1-C8烷基)；R5 = (取代)芳基]。该方法包括将化学式为(I)的α-羟基酮，其中R1和R2如上定义，与具有化学式R3NH2的手性胺反应，其中R3 = R4R5CH-，其中，R4 = H、C1-8烷基、C4-6环烷基或-COOR6 (R6=C1-8烷基)，R5 = (取代)芳基]，以生成化学式为(II)的化合物，其中R1、R2和R3如上定义，随后还包括还原以形成化学式为(III)的化合物。